PTO/SB/05 (06-03)

Approved for use through 07/31/2003. OMB 0651-0032

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE sons are required to respond to a collection of information unless it displays a valid OMB control number

	UTILITY	Attor	ney Docket No.	F	PC25228A				
	APPLICATION	First	Inventor	┤.	Justin CHAPMAN				
	TRANSMITTAL			1 1	DIAGNOSTICS AND THERAPEUTICS FOR THE GENE EXPRESSION SIGNATURE OF PPAR-GAMMA RECEPTOR LIGAND				
t for any appearance to the second	70 5 D S4 52/h))				El 969716695 US				
	ICATION ELEMENTS eming utility patent application contents.		Express Mail Label No. El 969716695 US ADDRESS TO: Mall Stop Non-Provisional Patent Applications Commissioner for Patents Box 1450 Alexandria, VA 22313-1450						
(Submit an origina Applicant cla See 37 CFR Specification (preferred arr - Descriptiv - Cross Re - Statemen - Reference or a comp - Backgrou - Brief Sum - Brief Des - Detailed I - Claim(s) - Abstract 4. Drawing(s) (3) 5. Oath or Decl a. Nev b. Copy (for c i. Sig na 1.6 6 Application	[Total Pages angement set forth below) e title of the Invention ferences to Related Applications at Regarding Fed sponsored R&D e to sequence listing, a table, buter program listing appendix and of the Invention for the Invention for the Drawings (if filed) Description of the Disclosure 12 13 14 15 16 17 18 19 19 19 19 19 19 19 19 19	16. 17. supply t	Power of Attorney (when there is an assignee) English Translation Document (if applicable) Information Disclosure (IDS)/PTO-1449 English Translation Document (if applicable) Return Receipt Postcard (MPEP 503) (Should be specifically itemized) CD-ROM or CD-R 1231 Computer Readable Copy (CRF) b. Specification Sequence Listing on: i. CD-ROM or CD-R (2 copies) ii. Paper c. Statement verifying identity of above copies ACCOMPANYING APPLICATION PARTS 9. Assignment Papers (cover sheet & document(s)) 10. 37 CFR 3.73(b) Statement Power of Attorney (when there is an assignee) 11. English Translation Document (if applicable) 12. Information Disclosure Copies of IDS Citations 13. Preliminary Amendment 14. Return Receipt Postcard (MPEP 503) (Should be specifically itemized) 15. Certified Copy of Priority Document(s) (if foreign priority is claimed)						
Prior application For CONTINUATION OR DI 5b, is considered a part of The incorporation can only	/ISIONAL APPS only; The entire disclosure of the disclosure of the accompanying continuation he relied upon when a portion has been inadvention.	tently or	nitted from the sub	mitted a	Group/Art L path or declarati reby incorporat pplication parts	ion is supplied under Box ed by reference.			
	19. CORRE	SPON	DENCE ADDR	にとろ					
Customer Number	28940			01	Correspo	ondence address below			
Name									
Address					T	т			
City	State				Zip Code	 			
Country	Telephone				Fax				
NAME (Print/typ	e) Elsa Djyardi	Reg	gistration No. (A	\ttorney	/Agent)	45,963			
Signature	Cleaning			Date		March 3, 2004 by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estin			

					uction Act of 1995, no pe	ersons are r	equired to re	spona to a	Con	nplete if Kn	OWN	a o o			
FEE TRANSMITTAL										Assigned.					
for FY 2004					Filing Date				Herev	Herewith					
						First Named Inventor				Justin CHAPMAN					
Effective 10/01/2003. Patent fees are subject to annual revision.				er Name			To be	Assigned.							
Applicant claims small status. See 37 CFR 1.27				Art Uni	t				To be Assigned.						
Total Amount of Payment \$ 865.00						Attorne	Attorney Docket No. PC25228A								
MET	HOD OI	PAY	MEN	IT (check all the	at apply)					ULATION	(continued)				
☐ Check ☐ Credit Card ☐ Money ☐ Other ☐ None Order					3. ADI Large E	DITIONA Intity Sn	L FEE					Fee Pald			
☑ Deposit Account:					Fee Code	Fee (\$)	Fee Code	Fee (\$)		, 00 2000					
Deposit Account	ount in the control of the control o						130	2051	65	Surcharge -	Surcharge – late fee or oath				
Number Deposit Account	Agouron Pharmaceuticals, Inc.						50	2052	25	Surcharge-l					
Name The Director is authorized to: (check all that apply)						1053	130	1053	130	Non-English					
☐ Charge fee(s) indicated below ☐ Credit any overpayments					1812	2,520	1812	2,520		uest for Ex Parte ree:					
☐ Charge fee(s) indicated below ☐ Great any or open management of fee(s)					1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action						
Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.						1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action					
				CULATION		1251	110	2251	55	Extension for reply within first month			<u> </u>		
1. BASIC F	ILING I	EE				1252	420	2252	210	Extension for reply within second month Extension for reply within third month					
Large Enti	ty Sm	iall En		_		1253	950	2253	475 740	1	or reply within fou				
Fee Fee			ee :\		S Dald	1254	1,480	2254	740	Extension	or reply within roa	iui monu.	1		
Code (\$) 1001 770			385	Fee Description Utility filing fee	Fee Paid 770	1255	2,010	2255	1,005	Extension for reply within fifth month Notice of Appeal					
1002 340	200	_	170	Design filing fee		1401 1402	330 330	2401	165 165		ppear of in support of an	appeal			
1003 530		-	265 385	Plant filing fee Reissue filing fee	.	1403	290	2403	145	Request for oral hearing					
1004 770 1005 160			305 80	filing fee	´ 	1451	1,510	1451	1,510	Petition to i	nstitute a public use p	roceeding			
1005 160	1200	5	00	ming 100		1452	110	2452	55	Petition to	evive unavoidabl	е			
		s	ubto	tal (1)s	\$ 770	1453	1,330	2453	665	Petition to	revive – unintentio	onal			
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE						1501	1,330	2501	665	Utility issue	fee (or reissue)				
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE Extra Claims Fee from Fee Paid					1502	480	2502	240	Design issue fee						
below Total Claims 21						1503	640	2503	320	Plant issue fee					
Total Claims	21		20** =		3 = 86	1460	130	1460	130						
Claims	Claims					50	1807	50	Processing fee under 37 CFR 1.17(q)						
Multiple Dependent 0 = 0					1807 1806	50 180	1807	180	Submission of Information Discbsure Strnt						
	_		•			1,300	.00	.555							
Large Entity Fee Fee			ee	Fee Description		8021	40	8021	40	Recording	each patent assignes number of p	gnment per			
Code (\$)	18 22	-	\$) 9	Claims in excess of	of 20	1809	770	2809	385	property (times number of properties) Filing a submission after final rejection (37 CFR 1.129(a))					
	36 22	01	43	Independent claim	s in excess of 3	1810	770	2810	385	For each additional invention to be examined (37 CFR 1.129(b))					
1203 2	90 22	03	145	Multiple dependen	t claim, if not paid	1801	770	2801	385	1					
1204	86 22	04	43	**Reissue indeper	ndent claims over original patent	1802	900	1802	900	Request for expedited examination of a design application					
1205	18 22	05	9 '	**Reissue independ original patent		Other Fee (specify)									
				matem Fac Balasiis	(\$) 95	*Redu	iced by Bas	sic Filina	Fee Paid	s	ubtotal (3)	(\$)	0		
		usiy pai	a, if gr	eater; For Reissue	o, see anove	1,000		9			f applicable)				
SUBMITTE Name (Prin		e)	Elsa	Djuardi			istration N		,963		Telephone	858 638	8-6117		
110,110 (1 111				·		(Atto	omey Age	nt)			Date:	March	3, 2004		
Signature			<u> </u>	guann	n this form may be	come cul	blic Credit	card in	formation	n should not					

Warning: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on including gathering, preparing, and submitting the completed application form to the USPTO. The will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and /or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and the amount of time you require to commerce, P.O. Box 1450, Alexandria; VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need essistance in completing the form, cell 1-800-pto-9199 and select option?

PC25228A Non-Provisional Application Certificate of Mailing (37 C.F.R. §1.10):
I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail (EL 96916695 US) in an envelope addressed to: Mail Stop: Patent Applications, Commissioner for Patents,
PO Box 1450, Alexandria, VA 22313-1450

on this 3rd day of March 2004.

Pamela Hollander, M.A.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: Justin CHAPMAN, et al.

Serial No.: Not Yet Assigned

Filed: Herewith

For: DIAGNOSTICS AND THERAPEUTICS FOR THE GENE EXPRESSION SIGNATURE OF PPAR-GAMMA RECEPTOR LIGAND

Mail Stop: Patent Applications

Honorable Commissioner For Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Examiner: Not Yet Assigned

Group Art Unit: Not Yet Assigned

TRANSMITTAL LETTER

Transmitted herewith are the following documents:

- 1. Return Receipt Postcard
- 2. Information Data Sheet
- 3. Utility Patent Application Coversheet
- 4. Specification
 - Claims
 - Abstract
 - Drawings
- 5. Fee Transmittal Sheet

1 Postcard;

2 pages;

1 page;

93 total pages;

2 pages;

1 page;

12 pages;

Deposit Account (1 page + duplicate).

Date: March 3rd, 2004

Respectfully submitted,

Elsa Djuardi

Attorney For Applicants Registration No. 45,963

Agouron Pharmaceuticals, Inc./A Pfizer Company Patent Department

10777 Science Center Drive San Diego, California 92121 Phone: (858) 638-6117

Phone: (858) 638-6117 Fax: (858) 678-8233